Giancarlo L. Scaccia

Giancarlo L. Scaccia — patent litigation practice summary

Focus areas. Scaccia's practice centers on pharmaceutical patent litigation, particularly ANDA/Hatch-Waxman matters, according to his Greenberg Traurig firm profile, which also lists post-grant proceedings and IP-related due diligence as concentrations. His academic background is in the life sciences (B.A. in biochemistry and mathematics, NYU), and the case literature tied to him is overwhelmingly drug-formulation and small-molecule work — e.g., the Valtoco (diazepam nasal spray) ANDA family, Astellas/Basilea v. Cipla et al. (D. Del.) concerning a small-molecule/Hatch-Waxman dispute, and Fate Therapeutics/Whitehead Institute v. Shoreline Biosciences (S.D. Cal.), an induced-pluripotent-stem-cell case. He has also appeared on a Section 337 team in a lighting-technology investigation, so his docket footprint is not exclusively pharma.

Side preference. The tracked data show a single appearance, on the defense side (1 defendant, 0 plaintiff), and that pattern is consistent with the broader record: he has been admitted pro hac vice to represent ANDA filers/generic defendants such as Teva Pharmaceuticals USA and Annora Pharma, and his 2024 Patexia "ANDA Litigation Intelligence" Top 100 most-active listing comes in a firm practice that Patexia ranked third nationally for defendant-side ANDA performance. The one clear counter-example is Fate Therapeutics, where he was on the Greenberg Traurig team representing the patent-owning plaintiffs/appellants — so he is best described as primarily a defense-side ANDA/patent litigator who also works brand/patent-owner matters.

Firm context. He is a shareholder in Greenberg Traurig's Intellectual Property & Technology Practice in New York (previously listed at the firm as an associate and then of counsel). No prior law-firm history before Greenberg Traurig was located in public sources. As a student he served as an Alexander Fellow/junior law clerk to the Hon. Susan D. Wigenton (D.N.J., 2014).

Notable matters, PTAB, and credentials. In the tracked matter, Neurelis, Inc. v. Amneal Pharmaceuticals LLC, he appeared pro hac vice for the defendant in the Valtoco diazepam nasal spray litigation. Other verified representations include Teva (D. Del., pro hac vice granted Oct. 2021), Annora Pharma in Astellas Pharma v. Cipla (D. Del. 2024), and the Satco Products respondent team in the ITC lighting investigation tied to Satco v. Regents of the University of California, IPR2021-00794 — a petition-side post-grant matter; the firm bio independently confirms a post-grant practice, though I found no source establishing that he personally argued an IPR. In Fate Therapeutics v. Shoreline Biosciences, the district court granted summary judgment of noninfringement against his clients and the Federal Circuit appeal was dismissed by agreement (Nov. 2024) — an adverse result for the client, noted for accuracy. He is admitted in New York and New Jersey (2016) and holds a J.D., cum laude, from Benjamin N. Cardozo School of Law (2015).